GEA Group Reports Robust Q3 Performance With Strong Growth

GEA Group Aktiengesellschaft has reported strong financial results for the third quarter of 2026, reflecting a substantial rise in order intake and improved revenue and profitability. The order intake rose by 20.3% to EUR 1,651 million, demonstrating organic growth of 19.5%. The company’s revenue increased by 7.0% to EUR 1,461 million, with an organic growth of 6.2%.

EBITDA before restructuring expenses saw a significant increase of 12.6%, reaching EUR 261 million, while the EBITDA margin set a new record of 17.9%. GEA also achieved a record ROCE of 37.8%, up from 35.4% the previous year. Free cash flow surged to EUR 135 million, and net liquidity improved to EUR 115 million despite share buyback activities.

The company's outlook for fiscal year 2026 remains strong, with expectations of 6.0-8.0% organic revenue growth, an EBITDA margin of 17.0-17.4%, and a ROCE between 36.0% and 40.0%. CEO Stefan Klebert highlighted the effectiveness of the 'Mission 30' strategy and noted significant growth in GEA's pharmaceutical solutions.